A Medical Device Daily

Cambridge Display Technology (CDT; Cambridge, UK), Sumitomo Chemical (Tokyo) and Novaled (Dresden, Germany) plan to co-develop hybrid OLED devices combining both new polymer emitting layers and doped electron transport layers.

It is expected that these hybrid devices will offer further improvements in power efficiency without additional manufacturing complexity.

The parties have reached an agreement on how IP generated during the joint development agreement will be handled. In addition, Novaled will grant a license to CDT enabling CDT to add necessary Novaled device IP to its existing and future licenses. Each company will remain responsible to market its own materials resulting from this co-development.

"Novaled, with its Novaled PIN OLED technology, is a leader in high-efficiency OLED devices and a recognized supplier of specialised dopants and organic transport materials", said company CEO Gildas Sorin. "We are pleased to contribute to the development of P-OLED devices and look forward to a successful collaboration with CDT and Sumitomo Chemical. This co-development agreement is consistent with our strategy to promote our dopants in all organic electronic fields."

CDT develops polymer organic light emitting diodes (P-OLEDs).

Sumitomo Chemical develops products in the fields of basic chemicals, petrochemicals, fine chemicals, IT-related chemicals, agricultural chemicals, and pharmaceuticals.

Novaled AG is in the OLED (organic light-emitting diode) field and specializes in high efficiency long lifetime OLED structures and an expert in synthetic and analytical chemistry.

In other agreements:

• HemCon Medical Technologies (Portland, Oregon) reported it will use SanguiBioTech's (Witten, Germany) ChitoSkin technology platform to help further innovations in hemostatic bandages and wound care dressings for the acute care market.

HemCon will leverage Sangui's technology platform to enhance and expand its product offerings for surgical and wound care. HemCon developed the chitosan-based hemostatic HemCon Bandages and ChitoFlex dressings that are used by military and medical first responders as well as health care professionals around the globe.

HemCon retains exclusive worldwide market and distributing rights for products developed under this structured financial agreement. HemCon will submit developed products for U.S. approvals to the FDA, while Sangui will prepare documentation for registration in the European Union.

SanguiBioTech focuses on vascular and hemostasis products. The firm specializes in developing oxygen-carrying agents to treat blocked arteries, anemia or acute blood loss.

• Iris International (Chatsworth, California) a manufacturer of automated in vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, reported that its Iris Diagnostics (also Chatsworth) division has renewed its supply agreement for its automated urinalysis systems, related products and consumables with MAGNET Cooperative, one of the largest and most experienced shared-service organizations in the U.S.

Under the terms of the new three-year agreement with MAGNET Cooperative, effective May 8, MAGNET is offering the full line of the company's products, including the iQ 200 urine microscopy analyzer, the iQ Body Fluids Module, the Aution MAX AX-4280 automated urine chemistry analyzer, the iChem 100 semi-automated urine chemistry system, along with all related consumables and service agreements.

"With MAGNET serving more than 12,000 healthcare systems, including more than 775 acute-care hospitals, we are pleased that our flagship automated urinalysis systems will continue to be made available to a significant group of healthcare providers," said Thomas Warekois, president of Iris Diagnostics.

• CellCyte Genetics (CellCyte; Bothell, Washington) has entered into a collaborative research agreement with Northwestern University's Feinberg School of Medicine (Chicago) to perform an acute myocardial infarction (AMI) disease model study in mice using CellCyte's CCG-TH30 product candidate. The goal of the study is to evaluate the functional benefit of the CCG-TH30 therapy in a disease model outcome study representative of the AMI (heart attack) indication.

Douglas Losordo, MD, a leader in cardiovascular cell therapy research and director of the Feinberg Cardiovascular Research Institute, will serve as the principal investigator on the study.

"We are extremely pleased to collaborate with Dr. Losordo, as he is one of the pre-eminent leaders in cardiovascular regenerative medicine," said Ronald Berninger, PhD, CellCyte's chief scientific officer. "This is another important collaboration for our program, as it allows us to evaluate the functional outcome benefit of the CCG-TH30 therapy as compared to standard cell therapies where delivery agents aren't used."

CellCyte Genetics is engaged in the discovery, development and commercialization of stem cell-enabling therapeutic products.